The p53 mutation in chronic myeloid leukemia (CML) led to decreased overall survival and therapy resistance which was also closely correlated with the downstream proto-oncogenes BCL-2, TCL-1 and MCL-1. We in this study aimed to investigate the function of miR130a in p53 tumor suppressor signaling pathway. We performed microRNA (miRNA) expression profile analysis in CML cancer stem cells of 38 cases and extracted total RNA from peripheral blood of 143 cases. Standard curves of U6 and miRNA were made from 10-fold serial dilutions of the cDNA, which were quantified using real-time quantitative PCR with SYBR Green by ABI 7300. The p53 mutations and BCR/ABL mutation status analysis in CML patients were detected by PCR and direct sequencing. Candidate targets of miR130a of putative relevance in CML pathogenesis were analyzed by bioinformatics approach. We then used dual-luciferase activity assay to verify the target genes of miR130a and used western blot analysis to elucidate the mechanism of miR130a on modulating drug resistance. The levels of miR-130a expression in CML were significantly lower in poor prognostic subgroups, defined by prognostic factors including mutated BCR/ABL status, p53 and ATM deletions and p53 mutations. Furthermore, underexpression of miR-130a was significantly associated with shorter overall survival and treatment-free survival in CML patients. We demonstrated that miR130a function as tumor suppressors by inhibiting multiple anti-apoptosis proteins, including BCL-2, MCL-1 and XIAP. This was a direct effect because miR130a negatively regulated expression of a BCL-2/MCL-1/XIAP 3'untranslated region-based reporter construct. Transfection of miR130a mimics into CML cells from 30 patients without p53 aberrations led to significant increases in apoptosis compared with transfection with the miRNA control. Besides, enforced expression of miR130a had no significant drug-sensitization effect in CML cells from p53-attenuated patients. MiR-130a may have an important role in the pathogenesis of CML and may be useful for assessing prognosis in patients with CML. Moreover, miR130a may provide a possible therapeutic avenue and a sensitive indicator of the activity of the p53 in CML.
INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo massive clonal expansion. The disease progresses through three distinct phases-chronic phase, accelerated phase, and blast crisis-during which the leukemic clone progressively loses its ability to differentiate. 1, 2 Current therapies including allogeneic bone marrow transplantation and drug regimens not only prolong overall survival rate but also have considerable adverse effects. 3 Allogeneic bone marrow transplantation, the only curative treatment for CML, is associated with substantial morbidity and mortality and is limited to patients for whom a suitable donor is available. 4, 5 The mechanisms favoring the growth advantage of Philadelphia chromosome-positive cells over normal cells in CML are not fully elucidated but could be partly because of altered apoptosis and longer survival of CML clones. 6, 7 Also, little is known about the biologic characteristics of disease progression in CML.
Cell homeostasis is regulated by a balance between proliferation, growth arrest and apoptosis. 8 Until recently, studies on oncogenesis have focused on the regulation of cell apoptosis. The recognition that negative growth control, including growth arrest and programmed cell death, must be understood to comprehend how appropriate cell numbers are maintained and how alterations in any part of the equation can contribute to malignancy has led to a burst of work in this field. 9, 10 MicroRNAs are an extensive class of small noncoding RNAs (18-25 nt) , with a significant impact on a number of biological processes, including development, differentiation, growth, metabolism and tumorigenesis, 11 through direct binding to the 3′ un-translational region (3′-UTR) of target mRNAs. MicroRNAs can regulate gene expression by two modes, depending on the degree of complementarity with the mRNA targets, to suppress translation or induce mRNA degradation. 12 MicroRNAs can function as tumor suppressors or oncogenes based on whether or not the microRNAs specifically target oncogenes or tumor suppressor genes. 13, 14 Our previous research indicated that miR-130a was significantly downregulated in CML cancer stem cells and initially confirmed the miR-130a might be related to the occurrence and development of CML indicating the possible tumor suppressor gene effects of it. 9 The miR-130a family has the same 3′-UTR binding seed sequence. Recently, miR-130a has been reported to be upregulated in several types of cancer, such as hepatocellular carcinoma, non-small cell lung cancer, CML, pancreatic cancer and breast cancer; [15] [16] [17] [18] [19] [20] [21] however, miR-130a is downregulated in chronic lymphocytic leukemia and sickle cell anemia, 22, 23 indicating the complexity and diversity of the roles of miR-130a in tumorigenesis.
Nevertheless, the pattern of expression and role of miR-130a in CML carcinogenesis remains unknown. We thereby in this study investigated the expression and roles of miR-130a in CML development.
MATERIALS AND METHODS Reagents
The pBR322/Msp I was from MBI. Gel preparation reagents: acrylamide, N'N'-methylene-bis-acrylamide, urea, ammonium persulfate and SDS were from Sigma, St Louis, MO, USA. Tris (hydroxymethyl) aminomethane (Tris) and agarose were from Gibco (St Louis, MO, USA) BRL. dATP, dGTP, dCTP, dTTP were from Boehringer Mannheim (Mannheim, Germany). Trizol and Lipofectamin 2000 were from Invitrogen (Waltham, MA, USA). BMSCs from CML were grown in Dulbecco's modified Eagle's medium (L-DMEM), IMDM, DF12 (Life Technologies, San Diego, CA, USA), with platelet-derived growth factor BB (PDGF-BB, Sigma). The following antibodies were used: CD11a, CD29, CD31, CD34, CD44, CD45, CD73, CD105, CD106, CD166, CD184, HLA-ABC, HLA-DR (BD Biosciences, San Jose, CA, USA); anti-rabbit IgG-fluorescein isothiocyanate (FITC; Sigma), anti-mouse IgG-FITC (Sigma).
Patients and tissue samples
Prior informed consent was obtained from the patients for the collection of specimens in accordance with the guidelines of Affiliated Hospital of Guangdong Medical College, China, and the study protocols were approved by Affiliated Hospital of Guangdong Medical College Ethics Committee. All specimens were handled and made anonymous according to ethical and legal standards.
Preparation of cancer stem cells from CML
Human raw lipoaspirates from donors undergoing selective suctionassisted lipectomy were collected. The procedures were performed as described previously with some modifications. 4, 7 The raw liposuctioned aspirate was washed extensively with D-Hanks solution to remove contaminating blood and local anesthetics. The cells were washed two times and plated in T-75 tissue culture flasks at a density of 2 × 10 6 ml − 1 . Expansion medium contained 57% DMEM/F-12, 40% MCDB-201, 2% fetal calf serum, 10 ng ml − 1 epidermal growth factor, 10 ng ml − 1 plateletderived growth factor BB, 100 U ml − 1 penicillin and 100 g ml − 1 streptomycin. Once adherent cells were more than 70% confluent, they were detached with 0.125% trypsin and 0.01% EDTA, and replated at a 1:3 dilution under the same culture conditions.
Electrotransfection of K562 cells and generation of stable transfected cell lines
Twenty-four hours before electroporation, cells were divided and grown in appropriate medium so that they could reach the logarithmic phase during the electroporation. Cell concentration was 4 × 10 6 /ml. On the day of electroporation, cells were harvested and washed in phosphate-buffered saline twice, and then re-suspended in serum free 1640 medium at a concentration of 1.3 × 10 7 ml − 1 at room temperature; DNA (a maximum of 10 μg in 10 of 20 μl) was added to the bottom of eletroporation cuvette at room temperature; 300 μl of cell suspension was added to eletroporation cuvette mixed with DNA gently to avoid any bubbles and stored at room temperature; cuvette was then placed in the electroporation chamber and pulsed once with parameters of capacitor 950 μF and voltage 250 V; cuvette was removed and cells were mixed gently; cells were transferred to FBS containing medium for 48 h and then to the selection medium. microRNA primers in reverse transcription miR-130a: 5′-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA ACC GAT-3′ U6 snRNA: 5′-AAA ATA TGG AAC GCT TCA CGA ATT TG-3′
MicroRNA real-time PCR
A total of 1 × 10 2 -1 × 10 7 cells were harvested, washed in phosphatebuffered saline once, and stored on ice; completed cell lysate was prepared by addition of 600 μl lysis binding buffer and vertex; 60 μl microRNA aomogenete addictive was added to the cell lysate and mixed thoroughly by inverting several times; sample was stored on ice for 10 min, followed by addition of equal volume (600 μl) of phenol: chloroform (1:1) solution; sample was mixed by inverting for 30-60 s, and then centrifuged at 12 000 g for 5 min; the supernatant was transferred to a new tube and the volume was estimated; 1/3 volume of 100% ethanol was added and mixed; the mixture was loaded to the column at room temperature and centrifuged at 10 000 g for 15 s; the flow-though was collected and the volume was then estimated; 2/3 volume of 75% ethanol was added and miR-130a on inhibitory pathways of apoptosis in CML patients X Zhu et al mixed; the mixture was loaded to column at room temperature and centrifuged at 10 000 g for 15 s; the flow-through was discarded; 700 μl microRNA wash solution was added to the column, followed by centrifugation at 10 000 g for 10 s; the flow-through was discarded; 500 μl microRNA wash solution was added to the column, followed by centrifugation at 10 000 g for 10 s; the flow-through was discarded; the column was transferred to a new tube and 100 μl preheated elution solution (95°) was added at room temperature; RNA was collected by centrifugation at 12 000 g for 30 s.
Western blot
Cells were harvested, washed twice in phosphate-buffered saline, and lysed in lysis buffer (protease inhibitors were added immediately before use) for 30 min on ice. Lysate was centrifuged at 10 000 r.m.p. and the supernatants were collected and stored at − 70°C in aliquots. All procedures were carried out on ice. Protein concentration was determined using BCA assay kit (Tianlai Biotech, Life Technologies).
Data analysis
Image data were processed using SpotData Pro software (Capitalbio, St Louis, MO, USA). Differentially expressed genes were identified using SAM package (Significance Analysis of Microarrays, version 2.1, CapitalBio, Beijing, China).
RESULTS
The low expression of miR-130a correlated with BCR/ABL and p53 mutation in CML We examined the microRNA expression levels of miR-130a of peripheral blood of 143 samples (Information were shown in Table 1 ). The results showed that the low expression of miR-130a was correlated with BCR/ABL mutation ( Figure 1a ). We further divided the 143 samples into two groups according to fluorescent in situ hybridization and mutation assay, that was, p53 abnormal group (n = 56) and p53 normal group (without p53 deletions, mutations and ATM deletions) (n = 87). We observed the expression of miR-130a in the two groups and the results showed that the miR-130a expression in the p53 normal group was significantly increased than those in the p53 abnormal group (P = 0.023)( Figure 1b ). Of all the 56 cases with abnormal p53, 13 cases were only ATM mention without p53 abnormal, 17 cases were p53 mutation only, 11 cases were p53 deletion only and 15 cases with both p53 mutation and missing. There existed significant differences between p53 abnormal group and p53 normal group (Figure 1c ).
The prognostic analysis of miR-130a in CML Using the BCR/ABL gene mutation as the standard, receiver operating characteristic curve (ROC curve) analysis of miR-130a was done to determine the optimal values of the boundaries of their expression, the area under the curve was 0.655 and therefore, the optimum cut-off values were 6.73 (Figure 2a ). The median follow-up period was 31 (3-143) months and 9 cases (6.2%) died because of disease progression and the overall survival (OS) time of miR-130a low-expression group was significantly shortened (P = 0.0063) ( Figure 2b ). During the follow-up period, 39 cases (27.3%) of patients accepted treatment (with Gleevec-based scheme) because of disease progression and the median of total free survival in miR-130a low-expression group were 60 months and there existed statistical significance (P = 0.0211) (Figure 2b and c). The statistical results showed that miR-130a can be used to predict the survival condition based on BCR/ABL mutation status.
Association of miR-130a expression with clinical outcome of CML patients Follow-up data were available for all patients. The median followup duration was 30 months, ranging from 8 to 67 months. Univariate analysis of factors associated with recurrence free survival showed a significantly shorter survival in the patients with clinical classification stage C (P o 0.01), unfavorable cytogenetic abnormalities (P = 0.01), BCR/ABL mutation (P = 0.008) and lower miR-130a expression (P = 0.004, Table 1 ). Parameters such as patients' sex and age had no impact (all P40.05). On the other hand, the variables that were associated with poor OS on univariate analysis were also clinical classification stage C (P = 0.002), unfavorable cytogenetic abnormalities (P = 0.007), BCR/ABL mutation (P = 0.01) and lower miR-130a expression (P o 0.01, Table 1 ). Cox proportional-hazards multivariate analysis of the univariate predictors identified BCR/ABL condition, clinical stage, the cytogenetic abnormalities and the expression level of miR-130a as independent prognostic factors for recurrence free survival and OS ( Table 2) .
BCL-2, MCL-1 and XIAP were the target genes of miR-130a By bioinformatics prediction, we found that BCL-2, MCL-1 and XIAP were the target genes of miR-130a. Luciferase experimental results showed that the luciferase activity of the resistant cells in mimetic transfected with miR-130a was significantly lower that that in the controls. Although the luciferase activity of the resistant cells in inhibitors transfected with miR-130a was significantly higher that that in the controls. All these results showed that BCL-2, MCL-1 and XIAP were the target genes of miR-130a ( Figure 3 ).
BCL-2, MCL-1, TCL-1 and XIAP protein levels were significantly higher in patients with drug-sensitive CML cells To investigate the BCL-2, MCL-1, TCL-1 and XIAP protein levels in patients with drug-sensitive CML cells, we performed the western blot analysis to detect the BCL-2, MCL-1 and XIAP protein levels and the results showed that BCL-2, MCL 1-XIAP protein expression in some of the drug-resistant CML cells were significantly increased ( Figure 4) . Transfected miR-130a mimics significantly decreased the protein expression of BCL-1, MCL-1 and XIAP Western blot was used to detect the expression of BCL-2, MCL-1 and XIAP in miR-130a transfected mimics and controls in CML cells. The results showed that the expression of BCL-2, MCL-1 and XIAP in miR-130a transfected mimics were significantly lower than those in the controls which further proved that miR-130a could target suppress the BCL-2, MCL-1 and XIAP protein expression in CML ( Figure 5 ).
Transfected miR-130a significantly increased the CML sensitivity to Gleevec 38 cases of primary CML cells transiently transfected by liposome into the miR-130a mature body to overexpress the simulation and the transfected miR-150, miR-16, miR-130b, miR-23a and NTC were used as the controls. A total 3.5 μmol l − 1 Gleevec was added into the culture after 24 h of transfection and the apoptosis reaction of CML cells to Gleevec was observed 48 h later. The cell apoptosis rate was calculated 72 h after transfection using the following formula: Annexin-V+/PI-+Annexin-V+/PI+)/CD19+) ( Figure 6 ).
DISCUSSION
MicroRNAs (miRNAs) are a class of phylogenetically conserved short RNAs that suppress protein expression through base-pairing with the 3′-untranslated region (3′-UTR) of target mRNA. Growing evidence suggests that miRNAs have important roles in diverse biological processes and the dysfunction of miRNAs is involved in the development of cancer. 24, 25 At present, cancer drug resistance is considered as a multifactorial phenomenon involving several major mechanisms, such as decreased uptake of water-soluble drugs, increased repair of DNA damage, reduced apoptosis, altered metabolism of drugs and increased energy-dependent efflux of chemotherapeutic drugs that diminish the ability of cytotoxic agents to kill cancer cells. 26 MiRNA expression affecting multiple genes simultaneously provided support for this hypothesis. 27 Mutations in the p53 tumor suppressor gene are found in nearly all types of cancers. 28 The transcription factor encoded by the p53 tumor suppressor gene is post-transcriptionally activated by DNA damaging agents/radiation, oxidative stress or activation of oncogenes. 29 The critical signals induced by these events are presumably DNA double-strand (ds) breaks, which activate ATM kinase that in turn phosphorylates p53. A number of additional modifications promote accumulation and increased transcriptional activity of p53, which directly regulates numerous target genes that mediate its diverse tumor suppressive effects. The induction of cell cycle arrest, which can be transient or permanent (senescence), and the promotion of apoptosis in cases in which the damage is too severe are considered to be important for p53mediated tumor suppression. The decision between these outcomes is determined by the level of p53 protein accumulation, with lower levels favoring arrest and higher levels promoting apoptosis. This effect is presumably because of differential affinities of p53-binding sites in the vicinity of target genes with miR-130a on inhibitory pathways of apoptosis in CML patients X Zhu et al pro arrest or cell death functions. Furthermore, proteins associating with p53 at specific promoters may influence this decision. miRNAs have been implicated in the regulation of processes that are deregulated in cancer cells, as proliferation, differentiation and apoptosis. 29, 30 Alterations in miRNA expression in cancer have been documented in numerous studies and suggest that miRNAs critically contribute to the characteristics of cancer cells. Furthermore, some miRNA-encoding genes have been classified as oncogenic or tumor suppressive genes according to their function in cellular transformation and altered expression in tumors. [11] [12] [13] Tumor suppressive miRNAs may function by downregulating the products of proto-oncogenes. For example, the miRNA family let-7 targets expression of the oncogenes KRAS, NRAS and HMGA2 and its expression is diminished in lung tumors. 31 Furthermore, the region encoding miR-15 and miR-16 is deleted in 65% of chronic lymphocytic leukemia and in other tumors. 32 As miR-15/16 targets the anti-apoptotic factor, BCL-2, the loss of miR-15/16 may explain the upregulation of BCL-2 in these tumors. 33 Recently, reports from several laboratories showed that members of the miR-34 family are direct p53 targets, and their upregulation induces apoptosis and cell cycle arrest. 34 We have previously reported that miR-130a was involved in the pathogenesis of CML 14 and we used the bioinformatics technology to predict the target genes miR-130a might regulate and the results showed that the number of the possible genes was more than 700. We paid special attention on the target gene associated with miRNA-mediated-specific cell phenotype which had already been reported and involved in the pathogenesis of CML stem cells resistant to disease genes. We found the key anti-apoptosis protein BCL-2, MCL-1 and XIAP were involved in the candidate genes by the help of function retrieval and literature review and their increased level were proved to be associated with the poor prognosis and drug resistance.
In recent years, we have come to understand that the effectors of apoptosis are represented by a family of intracellular cysteine proteases known as caspases. 35, 36 Inhibiting caspases, however, does not always inhibit cell death induced by pro-apoptotic stimuli. Figure 3 . BCL-2, MCL-1 and XIAP were the target genes of miR-130a. (a) Luciferase experimental results showed that the luciferase activity of the resistant cells in mimetic transfected with miR-130a was significantly lower that that in the controls. (b) The luciferase activity of the resistant cells in inhibitors transfected with miR-130a was significantly higher that that in the controls. All these results showed that BCL-2, MCL-1 and XIAP were the target genes of miR-130a. *, # and^represents Po 0.05. Figure 4 . BCL-2, MCL-1, TCL-1 and XIAP protein levels were significantly higher in patients with drug-sensitive CML cells. We performed the western blot analysis to detect the BCL-2, MCL-1 and XIAP protein levels and the results showed that BCL-2, MCL 1-XIAP protein expression in some of the drug-resistant CML cells were significantly increased. CML, chronic myeloid leukemia. Figure 5 . Transfected miR-130a mimics significantly decreased the expression of BCL-1, MCL-1 and XIAP. (a) Western blot was used to detect the expression of BCL-2, MCL-1 and XIAP in miR-130a transfected mimics and controls in CML cells. The results showed that the expression of BCL-2, MCL-1 and XIAP in miR-130a transfected mimics were significantly lower than those in the controls which further proved that miR-130a could target suppress the BCL-2, MCL-1 and XIAP protein expression in CML. (b) RT-PCR further confirmed expression of BCL-2,MCL-1 and XIAP in miR-130a transfected mimics were significantly lower than those in the controls. CML, chronic myeloid leukemia. miR-130a on inhibitory pathways of apoptosis in CML patients X Zhu et al Although caspase inhibitors block some or all of the apoptotic morphology induced by growth factor withdrawal, etoposide, actinomycin D, UV radiation, staurosporine, enforced c-Myc expression or glucocorticoids, they do not necessarily maintain replicative or clonogenic potential; ultimately, the cells die despite inactivation of caspases by way of a slower, non-apoptotic cell death. In contrast, anti-apoptotic proteins such as Bcl-2, Bcl-xL and oncogenic Abl can maintain survival and clonogenicity in the face of these treatments. [37] [38] [39] Conversely, some pro-apoptotic proteins such as Bax, a mammalian cell death protein that targets mitochondrial membranes, can induce mitochondrial damage and cell death even when caspases are inactivated. A variety of abnormal expression of BCL-2 family members existed in CML, for example, BCL-2, BAX and BAK expression increased, while BAD decreased, and the elevated BCL-2 led to cellular drug resistance by inhibiting pro-apoptotic proteins such as BAX and BAK. 40 Besides, ATM, MDM-2, MCL-1, Noxa and Puma were also found abnormal in the CML samples. 41 Furthermore, Bcl-2 proto-oncogene was found to be expressed on myeloid cells and their progenitors and is regulated in a differentiation-linked manner. MCL-1 was another member of BCL-2 family and MCL-1, which selectively inhibits the pro-apoptotic protein BIM, was essential both early in lymphoid development and later on in the maintenance of mature lymphocytes. 42 As a self-regulatory mechanism of cancer, MCL-1 often compensatory increased and was the reason of secondary resistant to the first-line therapy in many cancers. Several studies have found that the abnormal expression of the anti-apoptotic gene XIAP was involved in tumor formation by leading to inhibition of apoptosis induced by chemotherapeutic drugs and promoting tumor metastasis. 43, 44 At the same time XIAP targeted Figure 6 . Transfected miR-130a significantly increased the CML sensitivity to Gleevec 38 cases of primary CML cells transiently transfected by liposome into the miR-130a mature body to overexpress the simulation and the transfected miR-150, miR-16, miR-130, bmiR-23a and NTC were used as the controls. A total of 3.5 μmol l − 1 Gleevec was added into the culture after 24 h of transfection and the apoptosis reaction of CML cells to Gleevec was observed 48 h later. The results showed that transfected miR-130a significantly increased the CML sensitivity to Gleevec. CML, chronic myeloid leukemia. miR-130a on inhibitory pathways of apoptosis in CML patients X Zhu et al drugs in the animal model of solid tumor had also made encouraging pre clinical results and promoted the acceleration into human clinical trials. Gleevec (Imatinib) greatly reduces the number of leukemia cells in almost all patients with Philadelphia (Ph) chromosome-positive CML and has revolutionized treatment for newly diagnosed patients. 17, 45 Imatinib acts by inhibiting the kinase activity of the Bcr-Abl oncoprotein, thereby reversing the activation of the signal transduction pathway that underlies the leukemia; this in turn leads to death of affected cells. However, an appreciable minority of those patients who respond initially to imatinib subsequently lose their response in association with emergence of an imatinibresistant clone. The various mechanisms underlying this resistance are probably heterogeneous but one that is reasonably well defined is the expansion of leukemia subclones with mutations in the Bcr-Abl kinase domain that impair imatinib binding. The identification of such mutations, especially those present in the phosphatebinding loop (P-loop) of the kinase domain, appears in some series to be associated with a high probability of disease progression and relatively short survival. Gleevec activated the P53 and P53dependent target genes and induced apoptosis of precursor molecules BAX and downregulation of anti-apoptotic proteins such as BCL-2, ultimately leading to cell apoptosis. So the P53 mutation might a very important reason for CML drug resistance and therefore, the anti-apoptotic protein directly targeted P53 downstream protain such as BCL-2, MCL-1, XIAP, comparing to the drugs that target the traditional upstream pathways, could directly activate the mechanism of cell death and was more effective than traditional chemotherapy drugs in cancer treatment.
To further verify the miR-130a leading to CML drug resistance by affecting apoptosis, we upregulated the miR-150, miR-16, miR-23a, miR-130a and miR-451 expression in CML and confirmed the sensitivity of cells to chemotherapeutic drugs with the method of cytometry apoptosis detection and the results was consistent with previous hypothesis, namely, the overexpression of miR-150, miR-16, miR-23a, miR-181a and miR-451 could enhance the sensitivity of CML cells to Gleevec in vitro. Actually, the proapoptosis effects of miR-150, miR-16, miR-23a had already been confirmed in many cancer cell types and our study found that, comparing with miR-150, miR-16, miR-23a, miR-130a had more apparent apoptosis promoting effect. At the same time, we also found that, although in most CML cells, transfection of miR-181a could significantly enhanced the sensitivity of CML to Gleevec. But with P53 abnormal CML cells, overexpression of miR-150, miR-16, miR-23a, miR-130a and miR-451 had no obvious effects in promoting apoptosis suggesting that these miRNA promoted apoptosis depended on the integrity of P53 protein function.
Generally speaking, miR130a may have important roles in the pathogenesis of CML and may be useful for assessing prognosis in patients with CML. Moreover, miR130a may provide a possible therapeutic avenue and a sensitive indicator of the activity of the p53 in CML.
